Lifestyle News

Leading Australian SMS analytics service VidCorp rebrands to Tall Bob

MELBOURNE, Australia, Feb. 21, 2022 /PRNewswire/ -- Today mobile communications, engagement and analytics provider VidCorp announced a broad company rebrand to Tall Bob (www.tallbob.com). Having acquired premium MMS gateway, Thirdscreen (www.thirdscreen.com.au) in 2021, Tall Bob has cemented its position as a key leader for SMS and MMS within the accelerating industry of omnichannel...

Crystal Lagoons PAL™ Projects are Recognized as “Champion of Champions” for their Contribution to Reducing the Carbon Footprint.

AMSTERDAM, May 2, 2022 /PRNewswire/ -- The Public Access Lagoons™ projects that Crystal Lagoons is developing around the world could reduce 14 million tons in CO2 emissions, equivalent to 40% of the carbon footprint of the tourism and transportation industries. Through its contribution to furthering carbon neutrality in different economic and social activities this has led the so-called PAL™...

Tsit Wing announces positive profit alert: profit attributable to owners increase not less than 30%

HONG KONG, July 22, 2021 /PRNewswire/ -- Tsit Wing International Holdings Limited ("Tsit Wing", together with its subsidiaries, the "Group"; stock code: 2119.HK), an integrated B2B food and beverage solutions provider, announces positive profit alert today. The Group is expected to record an increase of approximately 30% to 35% in profit attributable to owners of the parent over that of...

Twist Alliance Pan-Cancer Methylation Panel Global Launch Event – A Strategic Collaboration Between AnchorDx and Twist Bioscience for Pan-Cancer Liquid Biopsy

GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), was launched globally on September 24th (US time). The Pan-Cancer Panel was developed over a two-year period by AnchorDx in collaboration with...

Mayne Pharma and Mithra Announce TGA Approval of NEXTSTELLIS® Oral Contraceptive

ADELAIDE, Australia, Nov. 30, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets). Mayne Pharma anticipates the commercial launch of NEXTSTELLIS by mid-2022 supported by...

Xiaohongshu debuts WILL Awards to recognize extraordinary up-and-coming Chinese brands

SHANGHAI, Sept. 15, 2021 /PRNewswire/ -- Xiaohongshu held its very first WILL Awards today to recognize promising young Chinese brands that resonate with consumers and represent the future of consumption in China. As a leading lifestyle platform, Xiaohongshu has incubated the rise of new consumer trends and witnessed the growth of emerging brands. Leveraging this influence, Xiaohongshu hopes that...

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents ≥12 to <18 in India

First authorization of Novavax' COVID-19 vaccine in adolescent population received Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India Authorization highlights immunogenicity and reassuring safety profile of Covovax in Phase 2/3 study of...

PINGTAN MARINE ENTERPRISE REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2021

Company to Hold Conference Call on Wednesday, May 18, 2022, at 8:30 AM ET FUZHOU, China, May 18, 2022 /PRNewswire/ -- Pingtan Marine Enterprise Ltd. (Nasdaq: PME) ("Pingtan" or the "Company"), a fishing company based in the People's Republic of China (PRC), today announced financial results for its fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Financial...

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis

SAN FRANCISCO and SUZHOU, China, Sept. 24, 2021 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial...

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and AnHeart Therapeutics Co., Ltd ("AnHeart"), a clinical-stage biopharmaceutical company committed to developing novel first-in-class or best-in-class precision oncology therapeutics,...

Recent Posts